Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1356 QT Interval Study
NCT02183467Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2008
- Primary completion
- Jun 2008
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of linagliptin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline of the individually heart rate-corrected QT interval (QTcI). Started Jan 2008; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02183467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183467.